Search Results

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units of the company’s common stock to 14 newly hired non-executive employees of the company.

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close.

Evolus, Inc. today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth.

Evolus, Inc. today announced that members of its management team will present at the following investor conferences in March.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 9,651 shares of Evolus and an aggregate of 20,971 restricted stock units of the company’s common stock to 10 newly hired non-executive employees of the company.

Evolus, Inc. today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units of the company’s common stock to 8 newly hired non-executive employees of the company.

Evolus, Inc. announced the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions.